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The crystal structures of an intermediate, C 10 H 9 ClN 4 O, 3-[(6-chloro-7H-purin-7-yl)methyl]cyclobutan-1-one (I), and two N-7 and N-9 regioisomeric oxetanocin nucleoside analogs, C 10 H 13 ClN 4 O, 3-[(6-chloro-8,9-dihydro-7H-purin-7-yl)methyl]cyclobutan-1-ol (II) and C 10 H 11 ClN 4 O, 3-[(6-chloro-9H-purin-9-yl)methyl]cyclobutan-1-ol (IV), are reported. The crystal structures of the nucleoside analogs confirmed the reduction of the N-7-and N-9-substituted cyclobutanones with LiAl(OtBu) 3 to occur with facial selectivity, yielding cis-nucleosides analogs similar to those found in nature. Reduction of the purine ring of the N-7 cyclobutanone to a dihydropurine was observed for compound (II) but not for the purine ring of the N-9 cyclobutanone on formation of compound (IV). In the crystal of (I), molecules are linked by a weak ClÁ Á ÁO interaction, forming a 2 1 helix along [010] . The helices are linked by offset -interactions [intercentroid distance = 3.498 (1) Å ], forming layers parallel to (101). In the crystal of (II), molecules are linked by pairs of O-HÁ Á ÁN hydrogen bonds, forming inversion dimers with an R 2 2 (8) ring motif. The dimers are linked by O-HÁ Á ÁN hydrogen bonds, forming chains along [001] , which in turn are linked by C-HÁ Á Á and offset -interactions [intercentroid distance = 3.509 (1) Å ], forming slabs parallel to the ac plane. In the crystal of (IV), molecules are linked by O-HÁ Á ÁN hydrogen bonds, forming chains along [101] . The chains are linked by C-HÁ Á ÁN and C-HÁ Á ÁO hydrogen bonds and C-HÁ Á Á and offset -interactions [intercentroid distance = 3.364 (1) Å ], forming a supramolecular framework.
Chemical context
Derivatives of naturally occurring nucleotides are an emerging class of antiviral therapeutics that are used to target tumors, herpes virus and the human immunodeficiency virus (HIV) (De Clercq, 2005) . The development of new and different nucleoside analogs is important in combating drug-resistant mutants and increasing therapeutic effectivity. The naturally occurring oxetanocin A, a nucleoside analog, demonstrated efficacy against herpes and HIV (Hoshino et al., 1987) . Further exploration of oxetanocin A derivatives such as cyclobut-A and cyclobut-B (Lobucavir) represented an increase in potency and metabolic stability (Hoshino et al., 1987; Bisacchi et al., 1991) . The current study focuses on the structural characterization of two nucleoside analogs, (II) and (IV), as well as the purinyl-cyclobutanone intermediate (I), prior to reduction. ISSN 2056-9890 
Structural commentary
The molecular structures of compounds (I), (II) and (IV) are illustrated in Figs. 1, 2 and 3, respectively. In compounds (I) and (II) there is a short intramolecular C-HÁ Á ÁCl interaction present (Tables 1 and 2 , respectively).
In compound (I) the purine ring is attached to the cyclobutanone unit through atom N7, rendering the attachment cis to the chlorine atom bound to the aromatic ring at the C6 position. The mean plane of the cyclobutane ring (A = C2 0 -C5 0 ) is inclined to the mean plane of the purine ring system (B = N1/N37N7/N9/C2/C4/C5/C6/C8) by 52.62 (11) , while the torsion angle N7-C5 0 -C4 0 Á Á ÁC2 0 is ca 125.4 . Reduction of compound (I) with lithium tri-tert-butoxyaluminum hydride lead to the formation of the oxetanocin derivative compound (II). Here the the mean plane of the cyclobutanol ring (A) is inclined to the mean plane of the The molecular structure of compound (IV), with the atom labelling. Displacement ellipsoids are drawn at the 50% probability level.
Figure 1
The molecular structure of compound (I), with the atom labelling. Displacement ellipsoids are drawn at the 50% probability level. The intramolecular C-HÁ Á ÁCl interaction (Table 1) is shown as a thin dashed line.
Figure 2
The molecular structure of compound (II), with the atom labelling. Displacement ellipsoids are drawn at the 50% probability level. The intramolecular C-HÁ Á ÁCl interaction ( (Fig. 2) .
In compound (IV), the cyclobutanol ring is attached to atom N9 of the purine ring (Fig. 3) . As a result of the trans positioning of the cyclobutanol unit, there are no intramolecular hydrogen bonds between the chlorine atom and the cyclobutanol or methylene connector as observed in compounds (I) and (II). Here, the mean plane of the cyclobutanol ring (A) is inclined to the mean plane of the purine ring system (B) by 71.20 (13) , and the torsion angle N7-C5 0 -C4 0 Á Á ÁC2 0 is ca 144.8 . Reduction of the purine ring of the N-7 cyclobutanone to a dihydropurine was observed for compound (II) but not for the purine ring of the N-9 cyclobutanone on formation of compound (IV). This is confirmed by the values of the bond lengths and bond angles involving atom C8; see Table 3 . Similar over-reductions of purine derivatives can be found in the literature, where electron-deficient purines are dearomatized by NaBH 4 to a dihydropurine (Aarhus et al., 2014) . We speculate the reason for over-reduction of the N-7 ketone may be due to the strain associated with the system. N-7 alkylation forces the chlorine of the purine ring to be oriented towards the cyclobutanone ring, which increases the strain energy of the system. This strain energy is released when the rigid aromatic structure of the purine is reduced to a more flexible dihydropurine (sp 2 C8 to sp 3 C8). This strained orientation is not observed for the N-9 ketone, hence the integrity of its purine ring is preserved.
Supramolecular features
In the crystal of (I), molecules are linked by a weak ClÁ Á ÁO interaction [Cl1Á Á ÁO1 0 (Àx + 1, y À , interplanar distance = 3.252 (1) Å , offset = 1.289 Å , symmetry code (i) Àx + 2, Ày + 1, Àz + 1.
In the crystal of (II), molecules are linked by pairs of N-HÁ Á ÁN hydrogen bonds, forming inversion dimers with an R Hydrogen-bond geometry (Å , ) for (I). Table 2 Hydrogen-bond geometry (Å , ) for (II).
Cg1 is the centroid of the N1/C2/N3/C4/C5/C6 ring. Symmetry codes: (i) Àx þ 2; Ày; Àz þ 1; (ii) x; y; z þ 1; (iii) Àx þ 1; Ày þ 1; Àz þ 1. Table 3 Hydrogen-bond geometry (Å , ) for (IV).
Cg1 is the centroid of the N1/C2/N3/C4/C5/C6 ring. Figure 5 
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, interplanar distance = 3.252 (1) Å , offset = 1.289 Å , symmetry code (v) Àx + 2, Ày + 1, Àz + 1.]
In the crystal of (IV), molecules are linked by O-HÁ Á ÁN hydrogen bonds (Table 3) , forming chains along direction [101] . The chains are linked by C-HÁ Á ÁO and C-HÁ Á ÁN hydrogen bonds, and C-HÁ Á Á (Table 4) and offsetinteractions, forming a supramolecular framework (see Fig. 6 ).
[Details of the offset -interactions: CgBÁ Á ÁCgB vi = 3.534 (1) Å , CgB is the centroid of the purine ring system, = 0.02 (10) Å , = 17.8
, interplanar distance = 3.364 (1) Å , offset = 1.08 Å , symmetry code (vi) Àx + 1, Ày + 1, Àz. ]
Database survey
A search of the Cambridge Structural Database (CSD, Version 5.40, update February 2019; Groom et al., 2016) found two related structure, viz. 6-chloro-9-(3-hydroxymethyl-3-hydroxycyclobutyl)purine (CSD refcode SOGROV; Boumchita et al., 1991)) and cis-1-bromomethyl-3-(6-chloro-9H-purinyl)cyclobutanol (ZUMHAQ; Gharbaoui et al., 1995) . The coordinates are not available for either structure.
Synthesis and crystallization
Synthesis of compounds (I) and (III): Potassium carbonate (12.0 mmol) was added to a solution of (3-oxocyclobutyl)methyl benzoate (10.0 mmol) in methanol (20 ml) and stirred for 1 h at room temperature. Saturated sodium bicarbonate (10.0 ml) was added and stirring continued for an additional 15 min. The solvent was evaporated under vacuum, followed by purification by flash column chromatography with ethyl acetate, resulting in 3-(hydroxymethyl)cyclobutan-1-one in 70% yield.
3-(Hydroxymethyl)cyclobutan-1-one (1 mmol) was dissolved in 10 ml of dry dichloromethane and cooled to 195 K. Hunig's base (3.2 mmol) was added, followed by trifluoromethanesulfonic anhydride (1 mmol) and the mixture was stirred for 10 min, cooled to 273 K and stirred to obtain the qualitative conversion to (3-oxocyclobutyl)methyl trifluoromethanesulfonate.
The (3-oxocyclobutyl)methyl trifluoromethanesulfonate (5.61 mmol) was added to a mixture containing 6-chloro-7H-purine (5.61 mmol), potassium hydroxide (5.61 mmol), tris[2-(2-methoxyethoxy)ethyl]amine (0.28 mmol), magnesium sulfate (2 g) and anhydrous acetonitrile (100 ml), which was then heated to 333 K for 5 h and cooled to room temperature. The product was purified using 5% methanol and 5% trimethylamine in chloroform, which yielded two UV-active compounds.
The two UV-active compounds were separated using flash column chromatography with ethyl acetate, giving 51% of the N-9 alkylated derivative; 3-[(6-chloro-9H-purin-9-yl)methyl]cyclobutan-1-one (III) and 37% of the N-7 alkylated derivative 3-[(6-chloro-7H-purin-7-yl)methyl]cyclobutan-1-one (I).
Synthesis of 3-[(6-chloro-8,9-dihydro-7H-purin-7-yl)methyl]cyclobutan-1-ol (II): 3-[(6-Chloro-7H-purin-7-yl)methyl]cyclobutan-1-one (I) (0.21 mmol) in dichloromethane (10 ml) was cooled to 195 K and lithium tri-tert-butoxyaluminum hydride was added. The mixture was cooled to room temperature and sodium borohydride (0.32 mmol) was added and the resulting mixture allowed to stir overnight. Methanol (2 ml) was added and the mixture allowed to stir overnight to convert the over-reduced 3-[(6-chloro-7H-purin-7-yl]methyl)cyclobutanone(I) to 3-[(6-chloro-8,9-dihydro-7H-purin-7-yl)methyl]cyclobutan-1-ol (II).
Synthesis of cis-3-[(6-chloro-9H-purin-9-yl)methyl]cyclobutan-1-ol (IV): 3-[(6-Chloro-9H-purin-9-yl)methyl]cyclobutan-1-one (III) (0.21 mmol) was added to diethyl ether and cooled to 195 K and lithium tri-tert-butoxyaluminum hydride (0.32 mmol) was added. The reaction was allowed to warm to room temperature and left to stir overnight, which provided quantitative conversion to cis-3-[(6-chloro-9H-purin-9-yl)-methyl]cyclobutan-1-ol (IV). Crystallization was achieved through evaporation over three days with tetrahydrofuran as the solvent. Figure 6 Pale-yellow plate-like crystals of (I), suitable for X-ray diffraction analysis, were obtained by slow evaporation of a solution in dichloromethane and heptane. Colourless platelike crystals of (II), were obtained by slow evaporation of a solution in methanol, dichloromethane and diethyl ether (1:1:1, 9 ml). Colorless plate-like crystals of (IV), were obtained by slow evaporation of a solution in methanol (3 ml) .
Refinement
Crystal data, data collection and structure refinement details are summarized in Table 5 . For all three compounds, C-bound H atoms were placed in calculated positions and refined as riding: C-H = 0.95-0.99 Å with U iso (H) = 1.2U eq (C). For compound (II), the OH and NH H atoms were located in a difference-Fourier map. While the OH H atom was freely refined the NH H atom was refined with a distance restraint: N-H = 0.86 (2) Å . For compound (IV), the OH H atom was located in a difference-Fourier map and freely refined. In compound (II), atoms C6 0 and C4 0 are positionally disordered and were split giving a refined occupancy ratio for C6 program(s) used to refine structure: SHELXL (Sheldrick, 2015) ; molecular graphics: PLATON (Spek, 2009) and Mercury (Macrae et al., 2008) ; software used to prepare material for publication: OLEX2 (Dolomanov et al., 2009) , PLATON (Spek, 2009) and publCIF (Westrip, 2010) .
3-[(6-Chloro-7H-purin-7-yl)methyl]cyclobutan-1-one (I)
Crystal data Special details Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (
C4-C5-C6-N1 1.4 (2) C4-N3-C2-N1 2.1 (3) N7-C5-C6-Cl1 2.9 (3) C6-N1-C2-N3 −1.5 (3) C4-C5-C6-Cl1 −178.08 (12) C2-N3-C4-N9 178.09 (16) C4-N9-C8-N7 −0.70 (19) C2-N3-C4-C5 −0.8 (2) C5-N7-C8-N9 0.4 (2) C8-N9-C4-N3 −i) x, y+1, z; (ii) x, −y+1/2, z+1/2.
3-[(6-Chloro-8,9-dihydro-7H-purin-7-yl)methyl]cyclobutan-1-ol (II)
Crystal data 
Data collection
Bruker-Nonius Kappa CCD diffractometer Radiation source: sealed X-ray tube, Enhance (Cu) X-ray Source Detector resolution: 7.9 pixels mm Special details Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. Symmetry codes: (i) −x+2, −y, −z+1; (ii) x, y, z+1; (iii) −x+1, −y+1, −z+1.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (

3-[(6-Chloro-9H-purin-9-yl)methyl]cyclobutan-1-ol (IV)
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (
